Wednesday, July 8, 2026

biotech · Systemic Lupus Erythematosus · Primary Progressive Multiple Sclerosis (PPMS) · ZBIO

Zenas BioPharma

Zenas BioPharma clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

1000 Winter St, Suite 1200, Waltham, MA 02451, US HQ
176 Employees
Public company Type
ZBIO · NYSE Ticker
Company details
Status
Public
HQ
1000 Winter St, Suite 1200, Waltham, MA 02451, US
Employees
176
Programs
13
Drugs
10
Patents
0
Intelligence · Clinical Programs

Zenas BioPharma projects

4 ClinicalTrials.gov programs sponsored by Zenas BioPharma.

Zenas BioPharma has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Obexelimab

    Zenas BioPharma

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial
  2. Obexelimab

    Zenas BioPharma

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial
  3. ZB012-02-001

    Zenas BioPharma

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial
  4. ZB012-02-002

    Zenas BioPharma

    RELAPSING MULTIPLE SCLEROSIS

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Zenas BioPharma have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.